Zobrazeno 1 - 10
of 499
pro vyhledávání: '"K Zarogoulidis"'
Autor:
M. Konoglou, P. Zarogoulidis, K. Porpodis, S. Androudi, D. Papakosta, D. Matthaios, T. Kontakiotis, V. Zervas, E. Kalaitzidou, A. Mitrakas, P. Touzopoulos, K. Zarogoulidis
Publikováno v:
Case Reports in Ophthalmology, Vol 2, Iss 3, Pp 360-366 (2011)
Small cell lung cancer is characterized by rapid growth and early metastasis. Despite its sensitivity to cytotoxic therapy, until now treatments have failed to control or cure this disease in most patients. Οrbital metastases are a rare manifestatio
Externí odkaz:
https://doaj.org/article/a7c4afa1c5c94bbfb388ea2176939c02
Autor:
P. Zarogoulidis, D. Matthaios, A. Iordanidis, V. Zervas, A. Mitrakas, G. Kouliatsis, K. Zarogoulidis
Publikováno v:
Case Reports in Oncology, Vol 4, Iss 1, Pp 155-161 (2011)
Thymic malignancies are rare intrathoracic tumors that may be aggressive and difficult to treat in advanced stage. Surgery is the cornerstone of the management of thymomas: it is significant for the definite histopathological diagnosis and staging, a
Externí odkaz:
https://doaj.org/article/22e77cce8228439b8454a010aeec6095
Autor:
P. Zarogoulidis, M. Orfanidis, T. C. Constadinidis, E. Eleutheriadou, T. Kontakiotis, T. Kerenidi, L. Sakkas, N. Courcoutsakis, K. Zarogoulidis
Publikováno v:
Case Reports in Medicine, Vol 2011 (2011)
Mesothelioma is a malignancy with poor prognosis, with an average 5-year survival rate being less than 9%. This type of cancer is almost exclusively caused by exposure to asbestos. A long exposure can cause mesothelioma and so can short ones, as each
Externí odkaz:
https://doaj.org/article/18755b921d3b416889ccd67e417b4a79
Pneumomediastinum is a rare clinical entity that concerns the clinicians in the emergency department. We present a case of a patient with spontaneous pneumomediastinum (Hamman's syndrome) that presented to our hospital's emergency department with cer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::40f154e011f727ca1f79b319a80fce2d
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3108003
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3108003
Autor:
Afroditi K. Boutou, K. Zarogoulidis, Maria Papaioannou, Kalliopi Chatzika, Paschalina Kontou, Katerina Manika, Ioannis Kioumis
Publikováno v:
The International Journal of Tuberculosis and Lung Disease. 19:1383-1387
Setting Rifampicin (RMP) has been reported to reduce moxifloxacin (MFX) levels, which may interfere with the effectiveness of MFX in treating tuberculosis (TB). Objective To study the MFX-RMP interaction in patients receiving MFX with or without RMP
Background: Despite the proof of principle that gene therapy can cure various monogenic diseases, limited clinical progress has been noted for gene therapy of the respiratory system. Certain anatomic features of the lungs, along with the suboptimal g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::1f2445a3b6e681d8db5e6f0d16f3ef8b
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3022061
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3022061
The Heimlich valve is a small one-way valve used for chest drainage that empties into a flexible collection device and prevents return of gases or fluids into the pleural space. The Heimlich valve is less than 13 cm (5 inches) long and facilitates pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::eb567a70f2584478b1605215437d5f0d
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3125268
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3125268
Autor:
S. Ramalingam, J. Crawford, A. Chang, C. Manegold, R. Perez-Soler, J.-Y. Douillard, N. Thatcher, F. Barlesi, T. Owonikoko, Y. Wang, P. Pultar, J. Zhu, R. Malik, G. Giaccone, S. Della-Fiorentina, S. Begbie, R. Jennens, J. Dass, K. Pittman, N. Ivanova, T. Koynova, P. Petrov, A. Tomova, V. Tzekova, F. Couture, V. Hirsh, R. Burkes, R. Sangha, M. Ambrus, T. Janaskova, J. Musil, J. Novotny, P. Zatloukal, J. Jakesova, K. Klenha, J. Roubec, J. Vanasek, J. Fayette, J. Bennouna-Louridi, C. Chouaid, J. Mazières, H. Vallerand, G. Robinet, P.-J. Souquet, D. Spaeth, R. Schott, H. Lena, Y. Martinet, C. El Kouri, N. Baize, A. Scherpereel, O. Molinier, F. Fuchs, K.M. Josten, N. Marschner, F. Schneller, T. Overbeck, M. Thomas, J. von Pawel, M. Reck, W. Schuette, V. Hagen, C.-P. Schneider, V. Georgoulias, I. Varthalitis, K. Zarogoulidis, K. Syrigos, C. Papandreou, C. Bocskei, E. Csanky, E. Juhasz, G. Losonczy, Z. Mark, I. Molnar, Z. Papai-Szekely, S. Tehenes, I. Vinkler, S. Almel, A. Bakshi, S. Bondarde, A. Maru, A. Pathak, R.M. Pedapenki, K. Prasad, S.V.S.S. Prasad, N. Kilara, D. Gorijavolu, C.D. Deshmukh, S. John, L.M. Sharma, D. Amoroso, E. Bajetta, P. Bidoli, A. Bonetti, F. De Marinis, M. Maio, R. Passalacqua, S. Cascinu, A. Bearz, M. Bitina, A. Brize, G. Purkalne, M. Skrodele, A.A. Baba, K. Ratnavelu, M.H. Saw, M.C. Samson-Fernando, G.E. Ladrera, J. Jassem, P. Koralewski, P. Serwatowski, M. Krzakowski, C. Cebotaru, D. Filip, D.E. Ganea-Motan, C.H. Ianuli, I.G. Manolescu, A. Udrea, O. Burdaeva, M. Byakhov, A. Filippov, S. Lazarev, I. Mosin, S. Orlov, D. Udovitsa, A. Khorinko, S. Protsenko, H.L. Lim, Y.O. Tan, E.H. Tan, R. Bastus Piulats, J. Garcia-Foncillas, J. Valdivia, J. de Castro, M. Domine Gomez, S.W. Kim, J.-S. Lee, H.K. Kim, J.S. Lee, S.W. Shin, D.-W. Kim, Y.-C. Kim, K.C. Park, C.-S. Chang, G.-C. Chang, Y.-G. Goan, W.-C. Su, C.-M. Tsai, H.-P. Kuo, M. Benekli, G. Demir, E. Gokmen, A. Sevinc, M. Haigentz, M. Agarwal, S. Pandit, R. Araujo, N. Vrindavanam, P. Bonomi, A. Berg, J. Wade, R. Bloom, B. Amin, R. Camidge, D. Hill, M. Rarick, P. Flynn, L. Klein, K. Lo Russo, M. Neubauer, P. Richards, R. Ruxer, M. Savin, D. Weckstein, R. Rosenberg, T. Whittaker, D. Richards, W. Berry, C. Ottensmeier, A. Dangoor, N. Steele, Y. Summers, E. Rankin, K. Rowley, S. Giridharan, H. Kristeleit, C. Humber, P. Taylor
Publikováno v:
Annals of Oncology. 24:2875-2880
Background Talactoferrin alfa is an oral dendritic cell (DC)-mediated immunotherapy (DCMI). We tested whether talactoferrin was superior to placebo in advanced non-small-cell lung cancer (NSCLC). Patients and methods An FORTIS-M trial was an internat
Autor:
Nikos K. Karamanos, Eugene P. Goldberg, K. Zarogoulidis, Ekaterini Chatzaki, P. Zarogoulidis, Wolfgang Hohenforst-Schmidt, T. Kontakiotis, G. Galaktidou
Publikováno v:
Cancer Gene Therapy. 19:593-600
Gene therapy can be defined as the transfer of genetic material into a cell for therapeutic purposes. Cytosine deaminase (CD) transferred into tumor cells by an adenoviral vector (Ad.CD), can convert the antifungal drug fluorocytosine (5-FC) to the a
Autor:
Th. Kontakiotis, A. Gotzamani-Psarrakou, G. Galaktidou, K. Zarogoulidis, Ellada Eleftheriadou, George Gerasimou, N. Karatzas, I. Sapardanis, Leonidas Sakkas, P. Zarogoulidis
Publikováno v:
Lung Cancer. 76:84-88
Background Long acting somatostatin analogues combined with platinum analogues have demonstrated an antiproliferative effect on growth of human SCLC xenographs. Method 130 previously untreated SCLC patients – 54 with limited disease (LD) and positi